Oncogenic dominant variants were observed in 4.2% of our cohort, of whom 2 individuals presented with P variants in BRCA2 and PALB2, both being linked to breast cancer and accounting together for 0.4% of our cohort. This evidence concerns the gene BRCA2 and breast cancer.